Search Results - "Frolich, L"

IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease by Winblad, B, Grossberg, G, Frölich, L, Farlow, M, Zechner, S, Nagel, J, Lane, R

“…The rivastigmine patch is the first transdermal treatment for Alzheimer disease (AD). By providing continuous delivery of drug into the bloodstream over 24…”
Get full text

Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum by Bos, Isabelle, Vos, Stephanie, Verhey, Frans, Scheltens, Philip, Teunissen, Charlotte, Engelborghs, Sebastiaan, Sleegers, Kristel, Frisoni, Giovanni, Blin, Olivier, Richardson, Jill C., Bordet, Régis, Tsolaki, Magda, Popp, Julius, Peyratout, Gwendoline, Martinez-Lage, Pablo, Tainta, Mikel, Lleó, Alberto, Johannsen, Peter, Freund-Levi, Yvonne, Frölich, Lutz, Vandenberghe, Rik, Westwood, Sarah, Dobricic, Valerija, Barkhof, Frederik, Legido-Quigley, Cristina, Bertram, Lars, Lovestone, Simon, Streffer, Johannes, Andreasson, Ulf, Blennow, Kaj, Zetterberg, Henrik, Visser, Pieter Jelle

“…We investigated relations between amyloid-β (Aβ) status, apolipoprotein E (APOE) ε4, and cognition, with cerebrospinal fluid markers of neurogranin (Ng),…”
Get full text

A 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease by WINBLAD, B, GROSSBERG, G, FRÖLICH, L, FARLOW, M, ZECHNER, S, NAGEL, J, LANE, R

“…The rivastigmine patch is the first transdermal treatment for Alzheimer disease (AD). By providing continuous delivery of drug into the bloodstream over 24…”
Get full text

Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study by Lleó, Alberto, Alcolea, Daniel, Martínez-Lage, Pablo, Scheltens, Philip, Parnetti, Lucilla, Poirier, Judes, Simonsen, Anja H., Verbeek, Marcel M., Rosa-Neto, Pedro, Slot, Rosalinde E.R., Tainta, Mikel, Izaguirre, Andrea, Reijs, Babette L.R., Farotti, Lucia, Tsolaki, Magda, Vandenbergue, Rik, Freund-Levi, Yvonne, Verhey, Frans R.J., Clarimón, Jordi, Fortea, Juan, Frolich, Lutz, Santana, Isabel, Molinuevo, José Luis, Lehmann, Sylvain, Visser, Pieter J., Teunissen, Charlotte E., Zetterberg, Henrik, Blennow, Kaj

“…Within-person trajectories of cerebrospinal fluid (CSF) biomarkers in Alzheimer's disease (AD) are not well defined. We included 467 subjects from the…”
Get full text

The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint by Jönsson, Linus, Wimo, Anders, Handels, Ron, Johansson, Gunilla, Boada, Mercè, Engelborghs, Sebastiaan, Frölich, Lutz, Jessen, Frank, Kehoe, Patrick Gavin, Kramberger, Milica, de Mendonςa, Alexandre, Ousset, Pierre Jean, Scarmeas, Nikolaos, Visser, Pieter Jelle, Waldemar, Gunhild, Winblad, Bengt

“…Lecanemab, an anti-amyloid antibody with effects on biomarker and clinical endpoints in early Alzheimer's Disease (AD), was granted accelerated approval by the…”
Get full text

The cholinergic pathology in Alzheimer's disease: discrepancies between clinical experience and pathophysiological findings by FRÖLICH, L

“…The cholinergic hypothesis of Alzheimer's disease (AD) states 1. that cholinergic neurons in the basal forebrain are severely affected in the course of…”
Get full text

Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer’s disease CSF profile of neuronal injury and inflammation by Neumann, Alexander, Küçükali, Fahri, Bos, Isabelle, Vos, Stephanie J. B., Engelborghs, Sebastiaan, De Pooter, Tim, Joris, Geert, De Rijk, Peter, De Roeck, Ellen, Tsolaki, Magda, Verhey, Frans, Martinez-Lage, Pablo, Tainta, Mikel, Frisoni, Giovanni, Blin, Oliver, Richardson, Jill, Bordet, Régis, Scheltens, Philip, Popp, Julius, Peyratout, Gwendoline, Johannsen, Peter, Frölich, Lutz, Vandenberghe, Rik, Freund-Levi, Yvonne, Streffer, Johannes, Lovestone, Simon, Legido-Quigley, Cristina, ten Kate, Mara, Barkhof, Frederik, Strazisar, Mojca, Zetterberg, Henrik, Bertram, Lars, Visser, Pieter Jelle, van Broeckhoven, Christine, Sleegers, Kristel

“…Alzheimer’s disease (AD) biomarkers represent several neurodegenerative processes, such as synaptic dysfunction, neuronal inflammation and injury, as well as…”
Get full text

Whole‐exome rare‐variant analysis of Alzheimer's disease and related biomarker traits by Küçükali, Fahri, Neumann, Alexander, Van Dongen, Jasper, De Pooter, Tim, Joris, Geert, De Rijk, Peter, Ohlei, Olena, Dobricic, Valerija, Bos, Isabelle, Vos, Stephanie J. B., Engelborghs, Sebastiaan, De Roeck, Ellen, Vandenberghe, Rik, Gabel, Silvy, Meersmans, Karen, Tsolaki, Magda, Verhey, Frans, Martinez‐Lage, Pablo, Tainta, Mikel, Frisoni, Giovanni, Blin, Oliver, Richardson, Jill C, Bordet, Régis, Scheltens, Philip, Popp, Julius, Peyratout, Gwendoline, Johannsen, Peter, Frölich, Lutz, Freund‐Levi, Yvonne, Streffer, Johannes, Lovestone, Simon, Legido‐Quigley, Cristina, Kate, Mara ten, Barkhof, Frederik, Zetterberg, Henrik, Bertram, Lars, Strazisar, Mojca, Visser, Pieter Jelle, Van Broeckhoven, Christine, Sleegers, Kristel

“…Introduction Despite increasing evidence of a role of rare genetic variation in the risk of Alzheimer's disease (AD), limited attention has been paid to its…”
Get full text

Assessing physician attitudes and perceptions of Alzheimer’s disease across Europe by Martinez-Lage, Pablo, Frölich, L., Knox, S., Berthet, K.

“…Given the important role that physicians play in clinical care, disease advocacy, national health policy making and clinical research, the IMPACT survey sought…”
Get full text

Realistic expectations for treatment success in Alzheimer's disease by Geldmacher, D S, Frolich, L, Doody, R S, Erkinjuntti, T, Vellas, B, Jones, R W, Banerjee, S, Lin, P, Sano, M

“…Alzheimer's disease (AD) is a progressive degenerative disease that warrants active management to delay or slow progression of its symptoms. The symptoms of AD…”
Get more information

A European Academy of Neurology guideline on medical management issues in dementia by Frederiksen, K. S., Cooper, C., Frisoni, G. B., Frölich, L., Georges, J., Kramberger, M. G., Nilsson, C., Passmore, P., Mantoan Ritter, L., Religa, D., Schmidt, R., Stefanova, E., Verdelho, Ana, Vandenbulcke, M., Winblad, B., Waldemar, G.

“…© 2020 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology. Background and purpose:…”
Get full text

Outcomes for clinical trials in mild-to-moderate dementia to evaluate drugs with presumably symptomatic effects by Frolich, L

Get more information

The clinical utility of structural neuroimaging with MRI for diagnosis and differential diagnosis of dementia: a memory clinic study by Hentschel, F., Kreis, M., Damian, M., Krumm, B., Frölich, L.

“…Objectives The individual contribution to the final comprehensive clinical diagnosis of neuropsychology (NP) and magnetic resonance imaging (MRI),…”
Get full text

Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype by Vermunt, Lisa, Sikkes, Sietske A.M., van den Hout, Ardo, Handels, Ron, Bos, Isabelle, van der Flier, Wiesje M., Kern, Silke, Ousset, Pierre-Jean, Maruff, Paul, Skoog, Ingmar, Verhey, Frans R.J., Freund-Levi, Yvonne, Tsolaki, Magda, Wallin, Åsa K., Olde Rikkert, Marcel, Soininen, Hilkka, Spiru, Luisa, Zetterberg, Henrik, Blennow, Kaj, Scheltens, Philip, Muniz-Terrera, Graciela, Visser, Pieter Jelle, Vellas, B., Reynish, E., Ousset, P.J., Andrieu, S., Burns, A., Pasquier, F., Frisoni, G., Salmon, E., Michel, J.P., Zekry, D.S., Boada, M., Dartigues, J.F., Olde-Rikkert, M.G.M., Rigaud, A.S., Winblad, B., Malick, A., Sinclair, A., Frölich, L., Scheltens, P., Ribera, C., Touchon, J., Robert, P., Salva, A., Waldemar, G., Bullock, R., Tsolaki, M., Rodriguez, G., Spiru, L., Jones, R.W., Stiens, G., Stoppe, G., Eriksdotter Jönhagen, M., Cherubini, A., Lage, P.M., Gomez-Isla, T., Camus, V., Agüera-Morales, E., Lopez, F., Savy, S., Cantet, C., Coley, N.

“…We estimated the age-specific duration of the preclinical, prodromal, and dementia stages of Alzheimer's disease (AD) and the influence of sex, setting,…”
Get full text

Consensus statement on dementia education and training in Europe by Tsolaki, M., Papaliagkas, V., Anogianakis, G., Bernabei, R., Emre, M., Frolich, L., Visser, P.J., Michel, J.-P., Pirttila, T., Olde Rikkert, M., Soininen, H., Sobow, T., Vellas, B., Verhey, F., Winblad, B.

“…Objectives The aim of the current statement is to agree on: (1) what is the current situation with education and training on dementia in Europe; (2) what are…”
Get full text

Prevalence and prognosis of Alzheimer’s disease at the mild cognitive impairment stage by Vos, Stephanie J. B., Verhey, Frans, Frölich, Lutz, Kornhuber, Johannes, Wiltfang, Jens, Maier, Wolfgang, Peters, Oliver, Rüther, Eckart, Nobili, Flavio, Morbelli, Silvia, Frisoni, Giovanni B., Drzezga, Alexander, Didic, Mira, van Berckel, Bart N. M., Simmons, Andrew, Soininen, Hilkka, Kłoszewska, Iwona, Mecocci, Patrizia, Tsolaki, Magda, Vellas, Bruno, Lovestone, Simon, Muscio, Cristina, Herukka, Sanna-Kaisa, Salmon, Eric, Bastin, Christine, Wallin, Anders, Nordlund, Arto, de Mendonça, Alexandre, Silva, Dina, Santana, Isabel, Lemos, Raquel, Engelborghs, Sebastiaan, Van der Mussele, Stefan, Freund-Levi, Yvonne, Wallin, Åsa K., Hampel, Harald, van der Flier, Wiesje, Scheltens, Philip, Visser, Pieter Jelle

“…© The Author (2015). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email:…”
Get full text

Genome-wide significant risk factors for Alzheimer’s disease: role in progression to dementia due to Alzheimer's disease among subjects with mild cognitive impairment by Lacour, A, Espinosa, A, Louwersheimer, E, Heilmann, S, Hernández, I, Wolfsgruber, S, Fernández, V, Wagner, H, Rosende-Roca, M, Mauleón, A, Moreno-Grau, S, Vargas, L, Pijnenburg, Y A L, Koene, T, Rodríguez-Gómez, O, Ortega, G, Ruiz, S, Holstege, H, Sotolongo-Grau, O, Kornhuber, J, Peters, O, Frölich, L, Hüll, M, Rüther, E, Wiltfang, J, Scherer, M, Riedel-Heller, S, Alegret, M, Nöthen, M M, Scheltens, P, Wagner, M, Tárraga, L, Jessen, F, Boada, M, Maier, W, van der Flier, W M, Becker, T, Ramirez, A, Ruiz, A

“…Few data are available concerning the role of risk markers for Alzheimer’s disease (AD) in progression to AD dementia among subjects with mild cognitive…”
Get full text

Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study by Lewczuk, P, Kamrowski-Kruck, H, Peters, O, Heuser, I, Jessen, F, Popp, J, Bürger, K, Hampel, H, Frölich, L, Wolf, S, Prinz, B, Jahn, H, Luckhaus, Ch, Perneczky, R, Hüll, M, Schröder, J, Kessler, H, Pantel, J, Gertz, H-J, Klafki, H-W, Kölsch, H, Reulbach, U, Esselmann, H, Maler, J M, Bibl, M, Kornhuber, J, Wiltfang, J

“…In this report, we present the results of a multicenter study to test analytic and diagnostic performance of soluble forms of amyloid precursor proteins α and…”
Get full text

Editorial: Lecanemab: Appropriate Use Recommendations - A Commentary from a European Perspective by Frölich, L, Jessen, F

Get full text

Discrimination between Alzheimer Dementia and Controls by Automated Analysis of Multicenter FDG PET by Herholz, K., Salmon, E., Perani, D., Baron, J-C., Holthoff, V., Frölich, L., Schönknecht, P., Ito, K., Mielke, R., Kalbe, E., Zündorf, G., Delbeuck, X., Pelati, O., Anchisi, D., Fazio, F., Kerrouche, N., Desgranges, B., Eustache, F., Beuthien-Baumann, B., Menzel, C., Schröder, J., Kato, T., Arahata, Y., Henze, M., Heiss, W-D.

“…A new diagnostic indicator of FDG PET scan abnormality, based on age-adjusted t statistics and an automated voxel-based procedure, is presented and validated…”
Get full text